The diagnostic landscape for systemic mastocytosis (SM) has evolved substantially with the implementation of ultra-sensitive molecular techniques.1 While traditional diagnostic criteria combine histopathology with clinical findings, the detection of activating KIT mutations serves as a critical minor diagnostic criterion present in over 90 percent of adult SM cases.2
Recent developments in molecular testing technology have dramatically improved diagnostic sensitivity. Digital droplet polymerase chain reaction (ddPCR) and advanced duplex sequencing can detect mutations at extremely low allele frequencies, far surpassing conventional sequencing methods that typically require substantially higher mutant allele burden.3 This enhanced sensitivity proves particularly valuable in indolent systemic mastocytosis (ISM), where patients often present with minimal bone marrow involvement and lower disease burden.3
Emerging data from recent clinical trials demonstrate that a subset of patients with confirmed ISM test negative by standard ddPCR but positive when ultra-sensitive duplex sequencing is employed.3 Notably, many of these patients still harbor activating KIT mutations detectable by advanced methods. This underscores that negative peripheral blood testing cannot definitively rule out SM, and bone marrow biopsy remains essential when clinical suspicion persists.
The ability to detect KIT mutations in peripheral blood represents a significant advance, with current sensitive techniques identifying mutations in a substantial proportion of SM patients. The expanding role of hematologists in ISM management reflects this diagnostic evolution alongside the availability of targeted therapies, shifting care toward a comprehensive approach that addresses underlying clonal disease rather than symptoms alone.4
The integration of advanced molecular diagnostics with traditional histopathologic assessment enables more accurate disease classification and supports timely implementation of targeted therapies. For patients with confirmed KIT mutations, tyrosine kinase inhibitors represent a treatment option that targets the underlying disease mechanism.1 Multiple agents in this class are available for consideration in appropriate clinical contexts. As diagnostic technologies continue advancing, the capacity to identify ISM earlier in its course may improve patient outcomes through prompt institution of appropriate management strategies.
Take our ISM quiz to see how your knowledge compares to your peers.
